TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01126879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Radical prostatectomy for treatment of prostate cancer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Radical prostatectomy for treatment of prostate cancer
Study: NCT03861429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me & My Wishes
Description: Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Me & My Wishes
Description: Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
Study: NCT00582192

Intervention type: OTHER
Intervention: Consult visit
Description: Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
Study: NCT01523028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Coffee
Description: Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Coffee
Description: Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Coffee
Description: Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter
Study: NCT03865862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
Study: NCT00411463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
Description: IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder.
Study: NCT00936195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz-Tenofovir-Emtricitabine
Description: Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine-Lamivudine-Lopinavir/Ritonavir
Description: Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day
Study: NCT00692445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-5214 + citalopram
Description: TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
Study: NCT01304030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy Training Modules
Description: The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residency Training as usual
Description: Residents will receive their typical didactic and clinical education
Study: NCT00314314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Description: Intranasal spray; 40 IU qid; 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluent
Description: Intranasal spray; 8 weeks
Study: NCT01113502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral formulation taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral formulation taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral formulation taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral formulation taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral formulation taken daily
Study: NCT01144026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.2mg)
Description: Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (1.0 mg)
Description: Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
Study: NCT03129854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prostate cryotherapy
Description: prostate cryotherapy added to experimental group within 6 months of ADT
Study: NCT00958581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
Study: NCT00692445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + citalopram
Description: Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
Study: NCT00958581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Description: For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
Study: NCT04289220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T Cells Injection
Description: Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
Study: NCT04444167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
Study: NCT03590756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16 weeks mango intake
Description: Participants will be provided fresh frozen Ataulfo mangoes.

Intervention type: OTHER
Group type: OTHER
Intervention: 16 weeks mango intake
Description: Participants will be provided fresh frozen Ataulfo mangoes.
Study: NCT03386201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylene blue
Description: Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
Study: NCT00107250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given daily; orally with approximately 240 ml of water whilst in an upright position

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
Study: NCT01274182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2013
Description: 1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
Study: NCT02002026

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Uterine artery ligation
Description: Uterine artery ligation during cesarean section before delivery of the baby

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery ligation
Description: Uterine artery ligation during cesarean section before delivery of the baby
Study: NCT02200796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Meal
Description: High carbohydrate meal
Study: NCT01265745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline for Injection
Description: Equivalent amounts to subjects weight, once over 120 minutes
Study: NCT02200796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Meal
Description: Omelet with 15 g of protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Protein Meal
Description: Omelet with 30 g of protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Meal
Description: Omelet with 45 g of protein
Study: NCT01290406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study: NCT01257841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin administration
Description: Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: Complete fasting, save for water and multivitamin, for four days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Complete fasting, save for water and multivitamin, for four days.
Study: NCT02718703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring System.
Description: In vitro diagnostic medical device
Study: NCT01225328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation/problem-solving (BA/PS)
Description: Six weekly telephone sessions to train participant in BA/PS procedures
Study: NCT02386059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: received normal saline, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg, intravenously, at the start of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg, intravenously, 15 minutes before the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone + Ondansetron
Description: 4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
Study: NCT04190654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Single oral dose of KW-6356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Single oral dose of KW-6356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Single oral dose of KW-6356
Study: NCT02036281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P-Saporin
Study: NCT00418873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotepine
Description: Oral
Study: NCT03494166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start with SMSH+TIPC
Description: See arm/group descriptions
Study: NCT00418873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral
Study: NCT03494166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start with SMSH alone
Description: See arm/group descriptions
Study: NCT00777374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch
Description: epicutaneous application of allergen patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: epicutanoeus application of a placebo patch
Study: NCT00952822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
Description: Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
Description: Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
Study: NCT02463617

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Study: NCT01265745

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MDX1303
Description: a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
Study: NCT01392924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT03428503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
Study: NCT04150744

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: take advantage of RFA to destroy hepatocellular carcinoma by high temperature

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation
Description: take advantage of RFA to destroy hepatocellular carcinoma by high temperature
Study: NCT03750149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeTracker
Description: Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
Study: NCT01521390

Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 62.5 mcg (one strip)
Description: GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 62.5 mcg(two strips)
Description: GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 125 mcg (one strip)
Description: GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 125 mcg(two strips)
Description: GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo, no active ingredient
Study: NCT01281644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser
Description: 810 nm diode laser
Study: NCT02524392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Independent medical evaluation
Description: The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
Study: NCT04519086

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Description: Low-dose computed tomography for suspected acute uncomplicated appendicitis in patients with BMI \>30

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: All patients with BMI \>30, who are diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
Study: NCT00611858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT00814294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule,0 units, quater in die (QID) for 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Description: Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Description: Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
Study: NCT01187979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash incentives
Description: Cash incentives paid to learners for reaching pre-determined milestones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills curriculum
Description: Standard department of education lifeskills curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life skills curriculum
Description: Standard department of education lifeskills curriculum
Study: NCT01324271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Tympanostomy Tube Delivery system (TTDS)
Description: placement of tympanostomy tube under local anesthesia
Study: NCT03592511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WGPF-burger
Description: Volunteers consumed a WGPF-burger daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control-burger
Description: Volunteers consumed a Control-burger daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control-burger
Description: Volunteers consumed a Control-burger daily
Study: NCT06099067

Intervention type: DRUG
Intervention: Canagliflozin
Description: Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication

Intervention type: DRUG
Intervention: DPP4 inhibitor
Description: DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications

Intervention type: DRUG
Intervention: DPP4 inhibitor
Description: DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications

Intervention type: DRUG
Intervention: Liraglutide
Description: Liraglutide dispensing claim is used as the Exposure drug in LEADER replication

Intervention type: DRUG
Intervention: Saxagliptin
Description: Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication

Intervention type: DRUG
Intervention: 2nd generation Sulfonylurea
Description: 2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication